{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T11:30:23Z","timestamp":1774870223588,"version":"3.50.1"},"reference-count":38,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,3,24]]},"abstract":"<jats:p>\n            High-level aminoglycoside resistance was noted in 30.0% of\n            <jats:named-content content-type=\"genus-species\">Enterococcus faecalis<\/jats:named-content>\n            and 25.2% of\n            <jats:named-content content-type=\"genus-species\">Enterococcus faecium<\/jats:named-content>\n            isolates. Only 3.3% and 2.1% of\n            <jats:named-content content-type=\"genus-species\">E. faecalis<\/jats:named-content>\n            isolates had elevated daptomycin MIC (\u22652\u2009mg\/liter) and vancomycin resistance, respectively. In contrast, 37.4% to 40.3% of\n            <jats:named-content content-type=\"genus-species\">E. faecium<\/jats:named-content>\n            isolates exhibited these phenotypes. Tedizolid inhibited 98.9% to 100.0% of enterococci causing serious invasive infections, including resistant subsets.\n          <\/jats:p>","DOI":"10.1128\/aac.00175-20","type":"journal-article","created":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T10:37:26Z","timestamp":1580294246000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":15,"title":["Assessment of Tedizolid\n            <i>In Vitro<\/i>\n            Activity and Resistance Mechanisms against a Collection of\n            <i>Enterococcus<\/i>\n            spp. Causing Invasive Infections, Including Isolates Requiring an Optimized Dosing Strategy for Daptomycin from U.S. and European Medical Centers, 2016 to 2018"],"prefix":"10.1128","volume":"64","author":[{"given":"Cecilia G.","family":"Carvalhaes","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer M.","family":"Streit","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2761"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014556879"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/2049936119828964"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000296"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw173"},{"key":"e_1_3_3_7_2","unstructured":"Merck and Co. Inc. 2017. Cubicin (daptomycin for injection) package insert. Merck and Co. Inc. Whitehouse Station NJ. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021572s059lbl.pdf."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu642"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy749"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00506-18"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00881-16"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0352-7"},{"key":"e_1_3_3_13_2","unstructured":"Cubist Pharmaceuticals U.S. 2014. Sivextro (tedizolid phosphate) package insert. Cubist Pharmaceuticals U.S. Lexington MA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205435s000lbl.pdf."},{"key":"e_1_3_3_14_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u201411th ed. CLSI document MO7","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u201411th ed. CLSI document MO7. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_15_2","volume-title":"Performance standards for antimicrobial susceptibility testing; 29th informational supplement. CLSI document M100","author":"Clinical and Laboratory Standards Institute","year":"2019","unstructured":"Clinical and Laboratory Standards Institute. 2019. Performance standards for antimicrobial susceptibility testing; 29th informational supplement. CLSI document M100. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_16_2","unstructured":"EUCAST. 2019. Breakpoint tables for interpretation of MICs and zone diameters version 9.0 January 2019. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_9.0_Breakpoint_Tables.pdf."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky188"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky099"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky088"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2016.174"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00355-19"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199603000-00012"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-200101000-00013"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2009.9930"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S54125"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.09.011"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02686-14"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00509-12"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx499"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06439-11"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S99046"},{"key":"e_1_3_3_32_2","volume-title":"Zyvox (linezolid) package insert","author":"Pfizer, Inc","year":"2008","unstructured":"Pfizer, Inc. 2008. Zyvox (linezolid) package insert. Pfizer, Inc., New York. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021130s016,021131s013,021132s014lbl.pdf."},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02216-16"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ444"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00609-17"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz367"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz109"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw312"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx251"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00175-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00175-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:32:52Z","timestamp":1645486372000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00175-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,24]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,3,24]]}},"alternative-id":["10.1128\/AAC.00175-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.00175-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,24]]},"assertion":[{"value":"2020-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00175-20"}}